Beta Pharma is an emerging specialty pharmaceutical company dedicated to the discovery, development and commercialization of innovative late stage therapies targeting oncology. Our products pipeline is diverse and undergoing rapid development. Beta Pharma Inc. was founded in 1996, at Science Park of Yale, as a contract research organization (named Beta Chemicals Inc.) to provide custom synthesis service for the pharmaceutical and biotechnology R&D community. In May of 2006, our novel EGFR inhibitor, Icotinib, entered into a Phase I clinical trial in China. The SFDA approved Icotinib on June 7, 2011. The global registration of Icotinib is undergoing, with our regional partners worldwide.